Highly rated in
Highly rated in
Check Dr. Amir A. Jazaeri's experience treating your condition:
About Dr. Amir A. Jazaeri

Amir Jazaeri is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Houston, Texas. Jazaeri has been practicing medicine for over 27 years and is highly rated in 17 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Endometrial Cancer, Oophorectomy, and Hysterectomy. He is licensed to treat patients in Texas and Virginia. Jazaeri is currently accepting new patients.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 27 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Amir A. Jazaeri it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Amir A. Jazaeri accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Community Health
1515 Holcombe Blvd, Houston, TX 77030
Background & Education
Graduate Institution
University Of Virginia School Of Medicine, 1996
Obstetrics and Gynecology
Gynecologic Oncology
Obstetrics & Gynecology in VA
Hospital Affiliations
UTMB - Texas Department Of Criminal Justice Hospital
University Of Texas MD Anderson Cancer Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
Evaluation of Safety and Immunogenicity of a Peptide Vaccine in Patients With Epithelial Ovarian or Primary Peritoneal Cancer
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
View 11 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors